: iStockAnalyst.com Symbols Feed

Hot Stocks Of The Day: CEPH, CI, CIEN, LDK, ZION

Mon, 23 Nov 2009 19:04:51 GMT

US stocks were higher in midday trade as better-than-expected housing data reinforced hopes of strong economic recovery.[More...]

Options Intelligence Report: Some McDonalds Put Sellers Are Lovin' It!

Mon, 09 Nov 2009 19:57:34 GMT

Today's tickers: MCD, SKS, VALE, V, GLD, AMR, ANF, CEPH, ESV, LXK, ANF & DISH[More...]

King Beats, But Earnings Down

Thu, 05 Nov 2009 20:08:54 GMT

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.[More...]

MFI Stock Review: Cephalon (CEPH)

Thu, 05 Nov 2009 16:56:11 GMT

Cephalon has three drugs with good growth potential. If sales develop according to the company's plan, the current price will prove to be a bargain.[More...]

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Thu, 24 Sep 2009 23:01:08 GMT

On 4/28/09, Dendreon (NASDAQ: DNDN) announced that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere.[More...]

Health Care Tops News This Morning: XOMA, CEPH, VVUS, CLZR, ELOS

Wed, 09 Sep 2009 16:50:01 GMT

The healthcare stocks remained in focus on Wednesday ahead of President Obama’s speech tonight on his healthcare reform effort. The healthcare space also witnessed heightened activity amid a flurry of corporate news.[More...]

Cheapest Stocks In The S&P 500 - High Value Score Stocks pt.3 - Stocks Include SPRINT NEXTEL (S) and PHILIP MORRIS INTL (PM)

Fri, 28 Aug 2009 17:58:35 GMT

Related: AES, APOL, AZO, CEPH, DNB, FIS, PM, s, TMO, TSO To identify potentially attractive investment ideas, The Applied Finance Group (AFG) uses a combination of proprietary variables including valuation, economic performance,[More...]

FDA Calendar Updates: POZN, AZN , SNY, CEPH, APPY, CYTR

Tue, 30 Jun 2009 18:24:20 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

Stocks To Watch : S&P 500 (ex. Financials)

Thu, 11 Jun 2009 15:02:33 GMT

The Applied Finance Group’s (AFG’s) Economic Margin (EM) methodology helps investors understand what a company earns above its true cost of capital or how profitable a firm is. Companies expected to improve their Economic Margins have proven to be more likely to outperform than companies with expected EM declines. The table below provides 10 stocks expected to improve their Economic Margins in the next fiscal year and look attractive from a valuation perspective according to AFG’s valuation model. All 10 of these firms also currently have a default buy recommendation and look to have considerable long-term upside. S&P 500 - Stocks to Watch (ex. Financials) [More...]

Top Picks For ASCO 2009

Tue, 26 May 2009 11:44:28 GMT

The ASCO annual meeting, one of the most important events in the pharmaceutical industry will take place in Orlando next weekend. With over 4,000 abstracts to be presented this year, separating the wheat from the chaff is difficult, but below is an incomp[More...]

Biotech firm Cephalon 3Q profit falls 2.7 percent

Tue, 27 Oct 2009 22:49:00 GMT

FRAZER, Pa. - Cephalon Inc. on Tuesday said third-quarter earnings fell from a year ago, when the biotech firm recorded a $66.1 million tax benefit.
Cephalon posted a net income of $102.7 million, or $1.31 per share, compared with $105.6 million, or $1.34, in the same period a year ago.
But Cephalon's adjusted earnings exceeded their average forecast of $1.41 per share.

: iStockAnalyst.com Symbols Feed

Hot Stocks Of The Day: CEPH, CI, CIEN, LDK, ZION

Options Intelligence Report: Some McDonalds Put Sellers Are Lovin' It!

King Beats, But Earnings Down

MFI Stock Review: Cephalon (CEPH)

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Health Care Tops News This Morning: XOMA, CEPH, VVUS, CLZR, ELOS

Cheapest Stocks In The S&P 500 - High Value Score Stocks pt.3 - Stocks Include SPRINT NEXTEL (S) and PHILIP MORRIS INTL (PM)

FDA Calendar Updates: POZN, AZN , SNY, CEPH, APPY, CYTR

Stocks To Watch : S&P 500 (ex. Financials)

Top Picks For ASCO 2009

Biotech firm Cephalon 3Q profit falls 2.7 percent

Xoma Raises $13.9 Million in Equity Financing

Omniture Deal a Milestone for Utah's Tech Sector: The $1.8 Billion Price Tag Would Make It the Largest Such Deal in the State's History.

Cephalon Q1 Net Income Up

Cephalon Offers A$318 Million to Acquire Arana

Peachtree Mall Owner May Seek Bankruptcy Protection: Mall's Firm Wrestling With High Debt, Slumping Retail Sales

Cephalon Completes Acquisition of Arana Therapeutics

BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update

Cephalon Delivers Record Sales in the Second Quarter 2009 ; Sales and Adjusted Net Income Exceed Guidance; NUVIGIL Launch Off to Strong Start

Cephalon Delivers Record Sales in the Second Quarter 2009

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit

Cephalon Quarterly Conference Call Invitation

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

Friday's News Makers - CarMax, Toyota, Cephalon, Harley Davidson, Electronic Arts; Research by InvestorSoup.com

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

Form 4 CEPHALON INC For: Dec 02 Filed by: VAUGHT JEFFRY L (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: SAVINI CARL A (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: Russell Lesley (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: Pappert Gerald J. (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: ROCHE ROBERT P JR (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: GREBOW PETER E (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: BUCHI J KEVIN (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: BALDINO FRANK JR (10K)

Form 4 CEPHALON INC For: Dec 02 Filed by: Baldassano Valli F. (10K)

Form 4 CEPHALON INC For: Dec 01 Filed by: VAUGHT JEFFRY L (10K)